Journey Medical Corp(DERM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 49.38% | Shs Outstand | 21.7M | Perf Week | -8.75% |
| Market Cap | 0.20B | Forward P/E | 10.46 | EPS next Y | 2035.71% | Insider Trans | - | Shs Float | 14.3M | Perf Month | 12.18% |
| Enterprise Value | 0.20B | PEG | - | EPS next Q | 0.01 | Inst Own | 37.77% | Short Float | 20.42% | Perf Quarter | 16.8% |
| Income | -0.01B | P/S | 2.94 | EPS this Y | 92.55% | Inst Trans | -6.87% | Short Ratio | 12.2 | Perf Half Y | -13.33% |
| Sales | 0.07B | P/B | 6.11 | EPS next 5Y | - | ROA | -6.8% | Short Interest | 2.92M | Perf YTD | -8.04% |
| Book/sh | 1.16 | P/C | 7.8 | EPS past 3/5Y | 34.88% - | ROE | -23.77% | 52W High | -25.8% ($9.56) | Perf Year | -1.94% |
| Cash/sh | 0.91 | P/FCF | - | Sales past 3/5Y | -5.66% 6.79% | ROIC | -11.61% | 52W Low | 64.5% ($4.31) | Perf 3Y | 140.34% |
| Dividend Est. | - | EV/EBITDA | 152.68 | EPS Y/Y TTM | 40.71% | Gross Margin | 59.26% | Volatility(W/M) | 4.43% 5.84% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.93 | Sales Y/Y TTM | 20.89% | Oper. Margin | -4.41% | ATR (14) | 0.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | 93.01% | Profit Margin | -8.95% | RSI (14) | 46.44 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.59 | Sales Q/Q | 23.33% | SMA20 | -3.89% ($7.38) | Beta | 1.1 | Target Price | $13.75 |
| Payout | - | Debt/Eq | 0.8 | Earnings | 2026/8/12 | SMA50 | 1.54% ($6.98) | Rel Volume | 1.11 | Prev Close | $7.45 |
| Employees | 58 | LT Debt/Eq | 0.64 | EPS/Sales Surpr. | 55.56% 0.82% | SMA200 | 2.19% ($6.94) | Avg Volume(3M) | 0.24M | Price | $7.09 |
| IPO | 2021/11/12 | Option/Short | Yes/Yes | Trades | 1980 | Volume | 265,028 | Change | -4.83% |
Company
DERM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Journey Medical (DERM) is a commercial-stage specialty pharmaceutical company focused on the sale and marketing of prescription therapeutics for skin conditions. It has secured multiple FDA-approved products across various dermatology areas, including acne, rosacea, and hyperhidrosis, and pursues a niche strategy of targeting dermatology specialists through its specialized sales organization rather than relying on large pharmaceutical companies.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
DERM has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +92.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +140.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 37.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BOUT 0.01%
KNOW 0.01%
QQQS 0.00%
IWC 0.00%
IWO 0.00%It ranks #4 in the industry
Based on market cap of $200M.
DERM $200M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is DERM?
DERM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of DERM?
The market cap of DERM is approximately $200M, ranking 4,116 within its sector.
What is the 52-week high and low for DERM?
DERM has recorded a 52-week high of $9.56 and a low of $4.31.
